Biological Assembly 1  

 3D View: Structure | Electron Density

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly 2  

 3D View: Structure | Electron Density

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B 

Biological assembly 2 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 98.46 kDa 
• Atom Count: 6907 
• Residue Count: 852 
• Unique protein chains: 2

3H3B

Crystal structure of the single-chain Fv (scFv) fragment of an anti-ErbB2 antibody chA21 in complex with residues 1-192 of ErbB2 extracellular domain

• DOI: 10.2210/pdb3H3B/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Homo sapiens, Mus musculus
• Expression System: Escherichia coli, Cricetulus griseus
• Mutation(s): No 


• Deposited: 2009-04-16 Released: 2010-04-28 
• Deposition Author(s): Zhou, H., Liu, Y., Niu, L., Zhu, J., Teng, M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.45 Å
• R-Value Free: 0.255 
• R-Value Work: 0.201 
• R-Value Observed: 0.203 

Literature

Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21.

Zhou, H., Zha, Z., Liu, Y., Zhang, H., Zhu, J., Hu, S., Shen, G., Cheng, L., Niu, L., Greene, M.I., Teng, M., Liu, J.

(2011) J Biol Chem 286: 31676-31683

• PubMed: 21680730 
• DOI: 10.1074/jbc.M111.235184
• Structures With Same Primary Citation


• PubMed Abstract: 
  

p185(her2/neu) belongs to the ErbB receptor tyrosine kinase family, which has been associated with human breast, ovarian, and lung cancers. Targeted therapies employing ectodomain-specific p185(her2/neu) monoclonal antibodies (mAbs) have demonstrated clinical efficacy for breast cancer. Our previous studies have shown that p185(her2/neu) mAbs are able to disable the kinase activity of homomeric and heteromeric kinase complexes and induce the conversion of the malignant to normal phenotype. We previously developed a chimeric antibody chA21 that specifically inhibits the growth of p185(her2/neu)-overexpressing cancer cells in vitro and in vivo. Herein, we report the crystal structure of the single-chain Fv of chA21 in complex with an N-terminal fragment of p185(her2/neu), which reveals that chA21 binds a region opposite to the dimerization interface, indicating that chA21 does not directly disrupt the dimerization. In contrast, the bivalent chA21 leads to internalization and down-regulation of p185(her2/neu). We propose a structure-based model in which chA21 cross-links two p185(her2/neu) molecules on separate homo- or heterodimers to form a large oligomer in the cell membrane. This model reveals a mechanism for mAbs to drive the receptors into the internalization/degradation path from the inactive hypophosphorylated tetramers formed dynamically by active dimers during a "physiologic process."

---

Organizational Affiliation: 

School of Life Sciences, Hefei National Laboratory for Physical Sciences at Microscale, Chinese Academy of Sciences, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230027, China.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Receptor tyrosine-protein kinase erbB-2	A, B	194	Homo sapiens	Mutation(s): 0  Gene Names: ERBB2, HER2, MLN19, NEU, NGL EC: 2.7.10.1
Find proteins for P04626 (Homo sapiens) Explore P04626  Go to UniProtKB:  P04626
NIH Common Fund Data Resources
PHAROS  P04626 GTEx  ENSG00000141736

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
anti-ErbB2 antibody chA21	C, D	259	Mus musculus	Mutation(s): 0  Gene Names: scFv of murine antibody A21

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.45 Å
• R-Value Free: 0.255 
• R-Value Work: 0.201 
• R-Value Observed: 0.203 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 82.177	α = 90
b = 87.2	β = 90
c = 108.52	γ = 90

Software Package:

Software Name	Purpose
MAR345dtb	data collection
PHASER	phasing
REFMAC	refinement
MOSFLM	data reduction
SCALA	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2009-04-16 
• Released Date: 2010-04-28 
Deposition Author(s): Zhou, H., Liu, Y., Niu, L., Zhu, J., Teng, M.

Revision History 

• Version 1.0: 2010-04-28
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Advisory, Version format compliance
• Version 1.2: 2011-09-28
  Changes: Database references